ID | 65907 |
フルテキストURL | |
著者 |
Miyamoto, Satoshi
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
Heerspink, Hiddo J. L.
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
de Zeeuw, Dick
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
Toyoda, Masao
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
Suzuki, Daisuke
Suzuki Diadetes Clinic
Hatanaka, Takashi
Department of Diabetes and Endocrinology, National Hospital Organization Fukuyama Medical Center
Nakamura, Tohru
Diabetes Internal Medicine, Sumitomo Besshi Hospital
Kamei, Shinji
Department of Diabetic Medicine, Kurashiki Central Hospital
Murao, Satoshi
Department of Diabetes and Endocrinology, Takamatsu Hospital
Hida, Kazuyuki
Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
Ando, Shinichiro
Department of Internal Medicine Diabetic Center, Okayama City Hospital
Akai, Hiroaki
Division of Diabetes and Metabolism, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
Takahashi, Yasushi
Department of Diabetes, Ochiai General Hospital
Koya, Daisuke
Department of Diabetology and Endocrinology, Kanazawa Medical University
Kitada, Munehiro
Department of Diabetology and Endocrinology, Kanazawa Medical University
Sugano, Hisashi
Department of Diabetes and Endocrinology, Kochi Health Sciences Center
Nunoue, Tomokazu
Nunoue Clinic
Nakamura, Akihiko
Internal Medicine, Osafune Clinic, Setouchi
Sasaki, Motofumi
Department of Diabetes and Endocrinology, Matsue City Hospital
Nakatou, Tatsuaki
Diabetes Center, Okayama Saiseikai General Hospital
Fujimoto, Kei
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University Kashiwa Hospital
Kawanami, Daiji
Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine
Wada, Takashi
Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University
Miyatake, Nobuyuki
Department of Hygiene, Faculty of Medicine, Kagawa University
Yoshida, Michihiro
Center for Innovative Clinical Medicine, Okayama University Hospital
Shikata, Kenichi
Center for Innovative Clinical Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
the CANPIONE study Investigators
|
抄録 | Aim: To evaluate the effect of canagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria.
Methods: The CANPIONE study is a multicentre, randomized, parallel-group and open-labelled study consisting of a unique 24-week preintervention period, during which the rate of eGFR decline before intervention is estimated, followed by a 52-week intervention and a 4-week washout period. Participants with a geometric mean urinary albumin-to-creatinine ratio (UACR) of 50 and higher and less than 300 mg/g in two consecutive first-morning voids at two different time points, and an eGFR of 45 ml/min/1.73m2 or higher, are randomly assigned to receive canagliflozin 100 mg daily or to continue guideline-recommended treatment, except for SGLT2 inhibitors. The first primary outcome is the change in UACR, and the second primary outcome is the change in eGFR slope. Results: A total of 258 participants were screened and 98 were randomized at 21 sites in Japan from August 2018 to May 2021. The mean baseline age was 61.4 years and 25.8% were female. The mean HbA1c was 7.9%, mean eGFR was 74.1 ml/min/1.73m2 and median UACR was 104.2 mg/g. Conclusions: The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria. |
キーワード | canagliflozin
CANPIONE study
diabetic kidney disease
eGFR slope
SGLT2 inhibitor
urinary albumin-to-creatinine ratio
|
発行日 | 2022-05-18
|
出版物タイトル |
Diabetes, Obesity and Metabolism
|
巻 | 24巻
|
号 | 8号
|
出版者 | Wiley
|
開始ページ | 1429
|
終了ページ | 1438
|
ISSN | 1462-8902
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2022 The Authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1111/dom.14731
|
ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
Citation | Miyamoto, S, Heerspink, HJL, de Zeeuw, D, et al. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study. Diabetes Obes Metab. 2022; 24(8): 1429-1438. doi:10.1111/dom.14731
|